See more : Gold Resource Corporation (GORO) Income Statement Analysis – Financial Results
Complete financial analysis of Nektar Therapeutics (NKTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nektar Therapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Plaza Centers N.V. (PLAZ-L.TA) Income Statement Analysis – Financial Results
- Bravada Gold Corporation (BGAVF) Income Statement Analysis – Financial Results
- North Bud Farms Inc. (NOBDF) Income Statement Analysis – Financial Results
- Shangying Global Co., Ltd. (600146.SS) Income Statement Analysis – Financial Results
- Xiamen Port Development Co., Ltd. (000905.SZ) Income Statement Analysis – Financial Results
Nektar Therapeutics (NKTR)
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.12M | 92.06M | 101.91M | 152.92M | 114.62M | 1.19B | 307.71M | 165.44M | 230.78M | 200.71M | 148.92M | 81.19M | 71.48M | 159.04M | 71.93M | 90.19M | 273.03M | 217.72M | 126.28M | 114.27M | 106.26M | 94.85M | 77.47M | 51.63M | 41.36M | 21.80M | 16.25M | 6.90M | 3.40M | 1.70M |
| Cost of Revenue | 36.64M | 21.64M | 24.90M | 19.48M | 21.37M | 24.41M | 30.55M | 30.22M | 34.10M | 28.53M | 38.51M | 30.43M | 21.89M | 25.67M | 30.95M | 35.04M | 147.52M | 118.09M | 36.00M | 19.80M | 14.68M | 7.02M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | -1.20M | -1.10M | -500.00K |
| Gross Profit | 53.48M | 70.42M | 77.01M | 133.44M | 93.24M | 1.17B | 277.16M | 135.22M | 196.68M | 172.17M | 110.41M | 50.76M | 49.59M | 133.37M | 40.98M | 55.15M | 125.51M | 99.63M | 90.28M | 94.47M | 91.58M | 87.83M | 73.30M | 51.63M | 41.36M | 21.80M | 16.25M | 8.10M | 4.50M | 2.20M |
| Gross Profit Ratio | 59.34% | 76.50% | 75.57% | 87.26% | 81.35% | 97.95% | 90.07% | 81.74% | 85.22% | 85.78% | 74.14% | 62.52% | 69.37% | 83.86% | 56.98% | 61.15% | 45.97% | 45.76% | 71.49% | 82.67% | 86.19% | 92.60% | 94.62% | 100.00% | 100.00% | 100.00% | 100.00% | 117.39% | 132.35% | 129.41% |
| Research & Development | 114.16M | 218.32M | 400.27M | 408.68M | 434.57M | 399.54M | 268.46M | 203.80M | 182.79M | 147.73M | 190.01M | 148.68M | 126.77M | 108.07M | 95.11M | 154.42M | 153.58M | 149.38M | 151.66M | 133.52M | 131.53M | 157.38M | 139.65M | 101.54M | 64.08M | 35.40M | 23.65M | 14.40M | 9.00M | 0.00 |
| General & Administrative | 77.42M | 92.33M | 122.84M | 104.68M | 98.71M | 81.44M | 52.36M | 44.28M | 43.27M | 40.93M | 40.53M | 41.61M | 46.76M | 40.99M | 41.01M | 51.50M | 56.34M | 78.32M | 43.85M | 30.97M | 22.02M | 26.02M | 18.86M | 13.93M | 7.87M | 8.39M | 6.33M | 4.00M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 77.42M | 92.33M | 122.84M | 104.68M | 98.71M | 81.44M | 52.36M | 44.28M | 43.27M | 40.93M | 40.53M | 41.61M | 46.76M | 40.99M | 41.01M | 51.50M | 56.34M | 78.32M | 43.85M | 30.97M | 22.02M | 26.02M | 18.86M | 13.93M | 7.87M | 8.39M | 6.33M | 4.00M | 3.20M | 7.40M |
| Other Expenses | 0.00 | -116.00K | -24.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 392.00K | 983.00K | 0.00 | 0.00 | 0.00 | -68.11M | -48.25M | 31.16M | 69.55M | 3.92M | 4.22M | 4.51M | 25.49M | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 4.30M | 7.90M |
| Operating Expenses | 190.90M | 310.66M | 523.11M | 513.36M | 533.28M | 480.98M | 320.83M | 248.08M | 226.05M | 188.66M | 230.54M | 190.29M | 173.53M | 149.05M | 136.12M | 137.80M | 161.66M | 258.86M | 265.06M | 168.41M | 157.76M | 187.91M | 184.00M | 115.48M | 71.95M | 43.79M | 29.97M | 19.60M | 13.30M | 7.90M |
| Cost & Expenses | 227.55M | 332.29M | 548.01M | 532.84M | 554.65M | 505.39M | 351.37M | 278.29M | 260.16M | 217.19M | 269.05M | 220.72M | 195.42M | 174.72M | 167.06M | 172.84M | 309.18M | 376.95M | 301.05M | 188.21M | 172.44M | 194.93M | 188.17M | 115.48M | 71.95M | 43.79M | 29.97M | 18.40M | 12.20M | 7.40M |
| Interest Income | 19.01M | 6.67M | 2.57M | 18.28M | 46.34M | 37.57M | 4.52M | 2.39M | 1.68M | 814.00K | 732.00K | 2.32M | 2.24M | 1.55M | 3.69M | 12.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.33M | 28.91M | 47.31M | 37.12M | 46.35M | 42.78M | 40.95M | 42.18M | 38.90M | 38.76M | 40.76M | 33.55M | 10.22M | 11.17M | 12.18M | 15.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.82M | 12.20M | 13.00M | 12.50M | 11.00M | 8.80M | 12.60M | 13.20M | 12.86M | 12.93M | 14.28M | 14.51M | 14.95M | 16.55M | 14.88M | 22.49M | 28.15M | 32.64M | 26.23M | 19.19M | 18.42M | 18.97M | 40.39M | 10.12M | 7.25M | 3.60M | 2.44M | 1.20M | 1.10M | 500.00K |
| EBITDA | -243.11M | -323.87M | -462.97M | -394.33M | -382.70M | 734.30M | -42.52M | -97.27M | -29.37M | -2.74M | -106.01M | -124.10M | -107.79M | -9.33M | -75.72M | 2.54M | -7.12M | -125.72M | -147.07M | -54.76M | -47.77M | -81.11M | -70.32M | -53.72M | -23.34M | -18.39M | -11.29M | -10.30M | -7.70M | -5.20M |
| EBITDA Ratio | -269.75% | -239.57% | -445.31% | -227.22% | -332.01% | 61.71% | -7.93% | -57.49% | -6.43% | -1.37% | -70.33% | -149.92% | -149.33% | 1.52% | -106.44% | -197.91% | -21.36% | -46.66% | -58.44% | -40.07% | -75.27% | -84.47% | 103.45% | -22.74% | -32.52% | -84.39% | -69.46% | -172.46% | -264.71% | -341.18% |
| Operating Income | -137.43M | -240.24M | -446.10M | -379.92M | -440.04M | 687.93M | -59.64M | -112.86M | -29.37M | -16.49M | -120.13M | -141.20M | -123.94M | -28.26M | -95.13M | -82.65M | -36.15M | -159.23M | -182.63M | -73.94M | -66.19M | -100.08M | -256.96M | -66.14M | -40.48M | -21.99M | -13.72M | -11.50M | -8.80M | -5.70M |
| Operating Income Ratio | -152.49% | -260.97% | -437.76% | -248.45% | -383.92% | 57.65% | -19.38% | -68.22% | -12.73% | -8.21% | -80.67% | -173.91% | -173.39% | -17.77% | -132.25% | -91.65% | -13.24% | -73.14% | -144.63% | -64.71% | -62.29% | -105.52% | -331.70% | -128.10% | -97.89% | -100.89% | -84.46% | -166.67% | -258.82% | -335.29% |
| Total Other Income/Expenses | -138.83M | -124.75M | -77.18M | -64.03M | -19.00K | -5.21M | -36.43M | -39.79M | -51.30M | -37.94M | -39.64M | -30.25M | -9.02M | -8.80M | -7.64M | 47.51M | 4.70M | 5.30M | -2.62M | -28.11M | 19.67M | -7.39M | 6.96M | -31.26M | -9.89M | 0.00 | 0.00 | 1.60M | 1.30M | 600.00K |
| Income Before Tax | -276.26M | -364.98M | -523.28M | -443.95M | -440.05M | 682.73M | -96.08M | -152.65M | -80.67M | -54.43M | -159.77M | -171.45M | -132.96M | -37.06M | -102.77M | 35.14M | -31.45M | -153.93M | -185.25M | -102.05M | -46.51M | -107.47M | -250.01M | -97.40M | -50.37M | 0.00 | 0.00 | -9.90M | -7.50M | -5.10M |
| Income Before Tax Ratio | -306.54% | -396.48% | -513.49% | -290.32% | -383.93% | 57.21% | -31.22% | -92.27% | -34.96% | -27.12% | -107.28% | -211.17% | -186.01% | -23.30% | -142.88% | 38.97% | -11.52% | -70.70% | -146.70% | -89.31% | -43.77% | -113.31% | -322.72% | -188.66% | -121.80% | 0.00% | 0.00% | -143.48% | -220.59% | -300.00% |
| Income Tax Expense | -200.00K | 3.22M | 557.00K | 493.00K | 613.00K | 1.41M | 616.00K | 876.00K | 506.00K | -512.00K | 2.25M | 406.00K | 1.02M | 881.00K | -253.00K | -806.00K | 1.31M | 828.00K | -137.00K | -163.00K | 169.00K | 7.39M | 139.31M | 33.56M | 7.85M | -3.63M | -3.74M | -1.50M | -1.10M | -400.00K |
| Net Income | -276.06M | -368.20M | -523.84M | -444.44M | -440.67M | 681.31M | -96.69M | -153.52M | -81.18M | -53.92M | -162.01M | -171.86M | -133.98M | -37.94M | -102.52M | -34.34M | -32.76M | -154.76M | -185.11M | -101.89M | -46.68M | -107.47M | -250.01M | -97.40M | -38.45M | -18.36M | -9.98M | -10.00M | -7.70M | -5.30M |
| Net Income Ratio | -306.31% | -399.98% | -514.03% | -290.65% | -384.47% | 57.09% | -31.42% | -92.80% | -35.17% | -26.86% | -108.79% | -211.67% | -187.43% | -23.85% | -142.52% | -38.07% | -12.00% | -71.08% | -146.59% | -89.16% | -43.93% | -113.31% | -322.72% | -188.66% | -92.96% | -84.22% | -61.44% | -144.93% | -226.47% | -311.76% |
| EPS | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 | -1.11 | -0.37 | -0.36 | -1.72 | -2.15 | -1.30 | -0.84 | -1.94 | -4.71 | -2.32 | -1.13 | -0.58 | -0.36 | -0.44 | -0.39 | -0.43 |
| EPS Diluted | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 | -1.11 | -0.37 | -0.36 | -1.72 | -2.15 | -1.30 | -0.84 | -1.94 | -4.71 | -2.32 | -1.13 | -0.58 | -0.36 | -0.44 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 190.00M | 187.14M | 183.30M | 178.58M | 174.99M | 180.12M | 155.95M | 139.57M | 132.46M | 126.87M | 115.73M | 114.82M | 112.94M | 94.08M | 92.77M | 92.41M | 91.88M | 89.79M | 85.92M | 78.46M | 55.82M | 55.28M | 53.14M | 42.00M | 34.02M | 31.44M | 27.58M | 22.73M | 19.74M | 12.33M |
| Weighted Avg Shares Out (Dil) | 190.00M | 187.14M | 183.30M | 178.58M | 174.99M | 180.12M | 155.95M | 139.60M | 132.46M | 126.87M | 115.73M | 114.82M | 112.94M | 94.08M | 92.77M | 92.41M | 91.88M | 89.79M | 85.92M | 78.46M | 55.82M | 55.28M | 53.14M | 42.00M | 34.02M | 31.44M | 27.58M | 22.73M | 19.74M | 12.33M |
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to...
Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and Chief Executive Officer Jonathan Zalevsky - Chief Research &...
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.32 per share a year ago.
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and investments in marketable securities at December 31, 2023, were $329.4 million...
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor,...
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
SAN FRANCISCO , Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets. Howard Robin,...
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
SAN FRANCISCO , Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 5:15 p.m.
Source: https://incomestatements.info
Category: Stock Reports